Iron Oxide Magnetic Resonance Imaging for Atherosclerosis Therapeutic Evaluation. Still "Rusty?"

Journal of the American College of Cardiology

Volumn 53, Issue 22, 2009, Pages 2051-2052

  Fayad, Zahi A ^a   Razzouk, Louai ^a   Briley Saebo, Karen C ^a   Mani, Venkatesh ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

carotid stenosis; inflammation; plaque vulnerability; statin; USPIO MRI

Indexed keywords

ATORVASTATIN; FLUORODEOXYGLUCOSE F 18; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE;

ARTERIAL WALL THICKNESS; ATHEROMA; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOPPLER ECHOGRAPHY; DRUG MEGADOSE; EDITORIAL; HUMAN; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; CAROTID STENOSIS; FERRIC COMPOUNDS; HEPTANOIC ACIDS; HUMANS; INFLAMMATION; MACROPHAGES; NANOPARTICLES; PYRROLES;

EID: 65649094414     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.03.021     Document Type: Editorial

References (14)

1. Ridker P.M., Danielson E., Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 359 (2008) 2195-2207
2. Braunwald E. Epilogue: what do clinicians expect from imagers?. J Am Coll Cardiol 47 (2006) C101-C103
3. Sanz J., and Fayad Z.A. Imaging of atherosclerotic cardiovascular disease. Nature 451 (2008) 953-957
4. Tang T.Y., Howarth S.P.S., Miller S.R., et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) study: evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol 53 (2009) 2039-2050
5. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 (2001) 1711-1718
6. Rudd J.H., Warburton E.A., Fryer T.D., et al. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105 (2002) 2708-2711
7. Ishii H., Aoyama T., et al. Effects of atorvastatin on F-18 fluorodeoxyglucose accumulation on positron emission tomography in atherosclerotic plaques: the EARDROP study (abstr). TT. Circulation 118 (2008) 109
8. Rudd J.H., Machac J., and Fayad Z.A. Simvastatin and plaque inflammation. J Am Coll Cardiol 49 (2007) 1991 author reply 1991-2
9. Tahara N., Kai H., Ishibashi M., et al. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. J Am Coll Cardiol 48 (2006) 1825-1831
10. Mani V., Briley-Saebo K.C., Itskovich V.V., Samber D.D., and Fayad Z.A. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP): sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 1.5T and 3T. Magn Reson Med 55 (2006) 126-135
11. Bellin M.F., Roy C., Kinkel K., et al. Lymph node metastases: safety and effectiveness of MR imaging with ultrasmall superparamagnetic iron oxide particles-initial clinical experience. Radiology 207 (1998) 799-808
12. McLachlan S.J., Morris M., Lucas M.A., and Baum L.M. Preliminary clinical experience with AMI 227. Acad Radiol 3 Suppl 2 (1996) 295-296
13. Briley-Saebo K., Bjornerud A., Grant D., Ahlstrom H., Berg T., and Kindberg G.M. Hepatic cellular distribution and degradation of iron oxide nanoparticles following single intravenous injection in rats: implications for magnetic resonance imaging. Cell Tissue Res 316 (2004) 315-323
14. Stadler N., Lindner R.A., and Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: evidence for the presence of elevated levels of iron and copper. Arterioscler Thromb Vasc Biol 24 (2004) 949-954